

COMPUS Diabetes Project — Guiding the Optimal Use of Insulin Analogues

Condition

Diabetes mellitus is a chronic disease characterized by the body's inability to produce enough insulin or to use it properly.

- Type 1 diabetes results when little or no insulin is made by the body.
- Type 2 diabetes results when the body makes insulin, but is unable to use it effectively.

Drug

- Insulin is a hormone that regulates the amount of glucose (sugar) found in the blood.
- Insulin analogues differ slightly in their chemical makeup from human insulins.
- Both rapid-acting (mealtime or bolus) and long-acting (background or basal) insulin analogues are available. They are used to treat patients with type 1, type 2, and gestational diabetes.

Issue

Within diabetes mellitus management, optimal use of the insulin analogues was identified by the COMPUS Advisory Committee as a priority topic. Given the high prevalence and rising incidence of diabetes in Canada, the optimal prescribing and use of insulin and insulin analogues has the potential to positively impact health outcomes for a large number of patients. Although the insulin analogues may have certain clinical advantages as compared to conventional insulins, acquisition costs of insulin analogues (i.e., insulin aspart, insulin lispro, insulin detemir, and insulin glargine) are greater than those for conventional insulin products (e.g., insulin neutral protamine Hagedorn [NPH] and regular human insulin). Given the increasing number of people diagnosed with diabetes mellitus each year, health care providers, consumers, and policy makers require evidence-based information on the optimal use of these agents.

Methods

Research efforts for the comparison of insulin analogues with conventional insulins focused on the following:

- clinical evaluation (systematic reviews and meta-analyses)
- economic evaluation (cost-effectiveness, cost-utility, and cost-consequence analyses)
- current utilization analysis
- current practice analysis
- identification of practice and knowledge gaps
- barriers to optimal use.

The clinical and economic evaluations were used by the COMPUS Expert Review Committee (CERC) to generate recommendations for the optimal prescribing and use of insulin analogues.

Results

- A total of 16 detailed optimal therapy recommendations were produced.
- Three gaps in knowledge and practice were revealed through comparing information from the Optimal Therapy Reports: *Current Utilization of Insulin Products in Canada*, and *Current Practice Analysis* with the *Optimal Therapy Recommendations for the Prescribing and Use of Insulin Analogues*.
- Key messages were developed based on the gaps and recommendations.
- COMPUS intervention tools will encourage the evidence-based optimal prescribing and use of insulin analogues.

Key Messages

Bolus insulin therapy:

- In patients with type 1 diabetes, either regular human insulin or rapid-acting insulin analogues can be considered as first-line therapy (except in adolescent patients).
- In adolescent patients with type 1 diabetes, rapid-acting insulin analogues may be considered as first-line therapy.
- In patients with type 2 diabetes requiring bolus insulin, regular human insulin may be considered first. Although the evidence is limited and inconsistent, patients who are experiencing significant hypoglycemia while taking human insulin may benefit from rapid-acting insulin analogues.

Basal insulin therapy:

- In patients with type 1 or type 2 diabetes requiring basal insulin, insulin NPH should be considered first. Although the evidence is limited and inconsistent, patients who are experiencing significant hypoglycemia while taking insulin NPH may benefit from long-acting insulin analogues.

This summary is based on the CADTH Optimal Therapy Reports on Insulin Analogues.

For complete Optimal Therapy Reports and
Intervention Tools: www.cadth.ca

The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgement in respect of the care of a particular patient or other professional judgement in any decision making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this Report.

CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions and views expressed herein do not necessarily represent the view of Health Canada or any Provincial or Territorial Government.

Production of this report is made possible through a financial contribution from Health Canada.